| Previous close | 90.82 |
| Open | 90.96 |
| Bid | 91.99 x N/A |
| Ask | 92.62 x N/A |
| Day's range | 90.82 - 90.82 |
| 52-week range | 80.89 - 104.24 |
| Volume | |
| Avg. volume | 1,155 |
| Market cap | 113.768B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 25.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.76 (4.14%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- Zacks
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.
- Zacks
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
- Bloomberg
French State Investment Firm Eyes Stake in Sanofi Consumer Unit
(Bloomberg) -- Bpifrance SACA is looking at a potential investment in Sanofi SA’s consumer health unit as it eyes bigger health investments, according to its executive director Jose Gonzalo.Most Read from BloombergBiden’s Fourth of July Shrouded by Pressure to Drop 2024 BidKamala Harris Is Having a Surprise Resurgence as Biden’s Campaign UnravelsSingapore Couples Are Marrying Earlier to Buy Homes, Leading Some to RegretNewsom Shocks California Politics by Scrapping Crime MeasureHouse Democrats C
© 2024 Yahoo. All rights reserved.